Dolutegravir + Lamivudine Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 50 mg / 300 mg
Reference Brands: Dovato(EU & US)
Category:
Anti Viral
Dolutegravir + Lamivudine is a two-drug HIV-1 treatment that combines an integrase inhibitor and an NRTI for effective viral suppression. Marketed as Dovato, it offers once-daily dosing, fewer side effects, and is FDA and EMA approved for treatment-naïve patients.
Dolutegravir + Lamivudine is available in Tablet
and strengths such as 50 mg / 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dolutegravir + Lamivudine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dolutegravir + Lamivudine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dolutegravir + Lamivudine is a fixed-dose combination antiretroviral medication used to treat HIV-1 infection in adults and adolescents. This two-drug regimen combines Dolutegravir, an integrase strand transfer inhibitor (INSTI), and Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI), to effectively suppress viral replication. Marketed under the brand name Dovato, it offers once-daily oral dosing with a simplified regimen, reducing pill burden. Approved by the US FDA and EMA, this dual therapy is recommended for treatment-naïve patients with no resistance to either drug. Dolutegravir + Lamivudine is known for its high efficacy, tolerability, and minimal side effects, supporting long-term HIV manageme
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing